The capability of our body cells to cease
blood loss following a vascular injury by forming blood clot is vital
to sustain health. Coagulation or clotting is the process of converting
the liquid blood into a gel like clot to cease bleeding. A number of
coagulation or clotting factors are involved in the route that leads to
the physiological procedure called hemostasis. Hemostasis is the
mechanism of clotting involving activation, adhesion, and aggregation of
platelets mediated by a number of clotting factors eventually leading
to repairing of the injured tissue. Any problem or absence of any of
these factors can potentially lead to a rare but serious blood clotting
disease and excessive bleeding. Some of the major coagulation factor
disorders are the hemophilias and Von Willebrand disease.
The global blood coagulation factor
market is anticipated to grow at a rapid pace owing to a multitude of
factors. Blood coagulation factors falls under the infusible hemostats
category. Developments in hemostasis technology has led to improvement
of wide range of products that have enabled clinicians to provide proper
emergency assistance to hemophilia patients. Factor VIII is a vital
blood clotting protein in the human body. Its deficiency caused by a
genetic defect results in a bleeding disorder called hemophilia A.
Factor VIII concentrates are obtained from human plasma or via
recombinant DNA technology to treat patients with hemophilia A. These
factor therapies are infused intravenously through a vein in the arm or a
port in the chest. Increase in the global trauma and accident cases is
another driver of the blood coagulation factor market. Growth in the
diagnosis rate of blood clotting diseases such as hemophilia and Von
Willebrand disease is also expected to drive the global blood
coagulation factor market during the forecast period. According to the
data by published The Centers for Disease Control and Prevention (CDC),
the incidence rate of hemophilia in the U. S. is 1 in every 5,000 male
births.
Von Willebrand disease (VWD), another
bleeding disorder, is the most commonly occurring blood disorder that
affects 1% of the population of the U.S. 1 in every 100 (almost 3.2
million) people in the U.S. is suffering from Von Willebrand disease
(VWD). Huge number of patients with bleeding disorders increase the need
for blood coagulation factor. Factor concentrates offer the most
promising treatment results in these diseases. However, stringent
regulatory policies and shortage in plasma supply can hamper the market
growth during the forecast period.
In terms of geography, the global blood
coagulation factor market can be segmented into North America, Europe,
Asia Pacific, Latin America, and Middle East & Africa. North America
is projected to remain the dominant markets for blood coagulation
factor market due to the high yield of plasma products, advancements in
technology, and increasing number of patients with blood disorders. Asia
Pacific is expected to expand at a high CAGR owing to the strong
economic growth, increase in the disposable income, rise in the health
care infrastructure, and growing investments by market players in this
region. India has the highest number of hemophilia patients in the
worlds. According to the Indian Genetic Disorder Database, there were an
estimated 55,000 hemophilia patients in India in 2015, of these 60% to
70% remain undetected. Moreover, the birth rate hemophilia in India is
32 per 1,000 births. Huge number of patients with bleeding disorders in
the country is expected to offer large opportunities in the blood
coagulation factor market in India.
Key players operating in the global blood
coagulation factor market include Baxter International Inc, CSL Ltd.,
Inc., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, and
Octapharma AG.
No comments:
Post a Comment